$69 non-ATF Mobile

Summary

  • Imugene has appointed Dr Rita Laeufle as its new Chief Medical Officer and a member of its executive leadership team.
  • Dr Laeufle will lead the Company’s global clinical development, medical monitoring, and regulatory activities.
  • Dr Laeufle holds extensive clinical development experience as a board-certified surgical oncologist and a scientist.
  • Imugene’s Executive Chairman, Mr Paul Hopper believes Dr Laeufle adds a critical capability to the Company’s senior leadership team.
  • Imugene is actively continuing with four clinical programs, associated with CHECKvacc (CF33 & anti-PDL1), VAXinia (CF33), PD1-Vaxx (PD-1) and HER-Vaxx (HER-2).
Gold MTF non-AMP

Clinical stage immuno-oncology company based in Australia, Imugene Limited (ASX:IMU) has recently announced the appointment of its new Chief Medical Officer (CMO). Imugene notified that it has hired Dr Rita Laeufle, MD PhD, as the CMO of the Company and a member of its executive leadership team.

Imugene shares traded at $0.051, up 8.5% mid-day on 1 October 2020.

Dr Laeufle has replaced Dr Mark Marino and will lead the Company’s global clinical development, medical monitoring, and regulatory activities. Dr Laeufle holds Doctor of Philosophy and Medical Doctor and degrees from Germany-based Albert Ludwig University of Freiburg. She studied the expression of neu/c-erbB-2 (HER-2) in human brain tumors as her PhD subject (Magna cum Laude).

Addition of Deep Experience to Imugene’s Leadership team

Dr Laeufle holds extensive clinical development experience as a board-certified surgical oncologist and a scientist. She has experience in immuno-oncology studies from Phase 1 to Phase 3 in gastrointestinal and breast cancers registration pathways.

Besides, she has held senior level clinical development, senior medical and leadership positions at multiple top-grade pharmaceutical companies, including Novartis Pharmaceuticals Corp and Hoffman-La Roche AG. Most recently, she was the CMO of a leading oncolytic virus firm based in San Diego CA, Oncolytics Biotech, where she will be based.

Imugene’s Executive Chairman, Mr Paul Hopper believes Dr Laeufle adds a critical capability to the Company’s senior leadership team.

Welcoming Dr Laeufle onboard, Imugene’s Managing Director and CEO, Ms Leslie Chong, said:

Dr Laeufle Enthusiastic to Join Imugene

Dr Laeufle is also excited to join the team of experts at Imugene that boasts a robust pipeline of innovative immunotherapy vaccines and oncolytic viruses.

Dr Laeufle believes that our understanding and knowledge of cancer biology has reached new dimensions in the present world. According to her, scientists across the world, with their enthusiasm and passion, have provided us with a future of novel immunotherapy agents that will assist cure and relieve the burden of the dreadful disease. By joining Imugene, she intends to drive towards safer and better treatments for the benefit of cancer patients.

Imugene is actively continuing with four clinical programs, associated with CHECKvacc (CF33 & aPDL1), VAXinia (CF33), PD1-Vaxx (PD-1) and HER-Vaxx (HER-2). The Company has recently secured option underwriting agreement with Bell Potter to raise ~$5.7 million to support its four progressing clinical programs.

Imugene believes that immunotherapies will continue to remain a foundation treatment for cancer disease over the coming years. Imugene’s goal is to ensure that the Company and its shareholders are at the vanguard of this fast-developing global market.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK